Mika Kontro

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 8

Top Topics

Acute Myeloid Leukemia

Bioinformatics Analysis

Drug Administration

Top Venues

Molecular cancer therapeutics

Science advances

This page only lists publications with an associated author ORCID identifier.

Publications

Samuli Eldfors, Joseph Saad, Nemo Koi Ikonen, Disha Malani, Markus Vähä-Koskela, Bjorn Tore Gjertsen, Mika Kontro, Kimmo Porkka, Caroline A Heckman
Monosomy 7/del(7q) Cause Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia. Blood advances (2024)
Tero Satomaa, Henna Pynnönen, Olli Aitio, Jukka O Hiltunen, Virve Pitkänen, Tuula Lähteenmäki, Titta Kotiranta, Annamari Heiskanen, Anna-Liisa Hänninen, Ritva Niemelä, Jari Helin, Heikki Kuusanmäki, Ida Vänttinen, Ramji Rathod, Anni I Nieminen, Emrah Yatkin, Caroline A Heckman, Mika Kontro, Juhani Saarinen
Targeting CD33+ acute myeloid leukemia with GLK-33, a lintuzumab-auristatin conjugate with a wide therapeutic window. Molecular cancer therapeutics (2024)
Samuli Eldfors, Joseph Saad, Nemo Ikonen, Disha Malani, Markus Vähä-Koskela, Bjorn Tore Gjertsen, Mika Kontro, Kimmo Porkka, Caroline A Heckman
Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia. Blood advances 8 (7) (2024)
Tero Satomaa, Henna Pynnönen, Olli Aitio, Jukka O Hiltunen, Virve Pitkänen, Tuula Lähteenmäki, Titta Kotiranta, Annamari Heiskanen, Anna-Liisa Hänninen, Ritva Niemelä, Jari Helin, Heikki Kuusanmäki, Ida Vänttinen, Ramji Rathod, Anni I Nieminen, Emrah Yatkin, Caroline A Heckman, Mika Kontro, Juhani Saarinen
Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab-Auristatin Conjugate with a Wide Therapeutic Window. Molecular cancer therapeutics 23 (8) (2024)
Samuli Eldfors, Joseph Saad, Nemo Ikonen, Disha Malani, Markus Vähä-Koskela, Bjorn Tore Gjertsen, Mika Kontro, Kimmo Porkka, Caroline A Heckman
Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia. Blood advances 8 (7) (2024)
Alisa Olkinuora, Taina T Nieminen, Suvi P M Douglas, Anni Kauppinen, Mika Kontro, Juho Väänänen, Matti Kankainen, Ari Ristimäki, Markus Mäkinen, Päivi Lahermo, Caroline A Heckman, Janna Saarela, Milla K Ahola, Anna Lepistö, Heikki Järvinen, Jukka-Pekka Mecklin, Outi Kilpivaara, Ulla Wartiovaara-Kautto, Kimmo Porkka, Päivi Peltomäki
Identification of DHX40 as a candidate susceptibility gene for colorectal and hematological neoplasia. Leukemia (2023)
Aleksandr Ianevski, Jenni Lahtela, Komal K Javarappa, Philipp Sergeev, Bishwa R Ghimire, Prson Gautam, Markus Vähä-Koskela, Laura Turunen, Nora Linnavirta, Heikki Kuusanmäki, Mika Kontro, Kimmo Porkka, Caroline A Heckman, Pirkko Mattila, Krister Wennerberg, Anil K Giri, Tero Aittokallio
Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. Science advances 7 (8) (2021)
Disha Malani, Ashwini Kumar, Oscar Bruck, Mika Kontro, Bhagwan Yadav, Monica Hellesøy, Heikki Kuusanmaki, Olli Dufva, Matti Kankainen, Samuli Eldfors, Swapnil Potdar, Jani Saarela, Laura Turunen, Alun Parsons, Imre Vastrik, Katja Kivinen, Janna Saarela, Riikka Raty, Minna Lehto, Maija Wolf, Bjorn Tore Gjertsen, Mohamed El Missiry, Tero Aittokallio, Krister Wennerberg, Caroline A Heckman, Olli Kallioniemi, Kimmo Porkka
Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer discovery (2021)